Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
US |
|
K
|
Kaman Corp
F:KA1
|
US |
|
Japfa Comfeed Indonesia Tbk PT
IDX:JPFA
|
ID |
|
S
|
STINAG Stuttgart Invest AG
XMUN:STG
|
DE |
|
Salim Ivomas Pratama Tbk PT
IDX:SIMP
|
ID |
|
Ariana Resources PLC
F:4A6
|
UK |
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
DK |
|
A
|
Atlantia SpA
XHAM:AU9
|
IT |
|
Delivra Health Brands Inc
OTC:DHBUF
|
CA |
|
Boyuan Holdings Ltd
ASX:BHL
|
AU |
|
M
|
McDonald's Corp
F:MDO
|
US |
Wall St Price Targets
REGN Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for REGN is 847.04 USD with a low forecast of 647.41 USD and a high forecast of 1 050 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is REGN's stock price target?
Price Target
847.04
USD
According to Wall Street analysts, the average 1-year price target for REGN is 847.04 USD with a low forecast of 647.41 USD and a high forecast of 1 050 USD.
What is the Revenue forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 8 years is 5%.
What is the Gross Profit forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 19%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Operating Income has been 18%. The projected CAGR for the next 8 years is 11%.
What is the Pre-Tax Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 22%. The projected CAGR for the next 3 years is 15%.
What is the Net Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 8 years is 8%.
